(Q38233740)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

A review of the management of elderly patients with non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

R Blanco

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

M G de la Torre

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

A Cassinello

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

I Nuñez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

24 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

451-463

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25060421%20AND%20SRC:MED&resulttype=core&format=json

The cancer survival gap between elderly and middle-aged patients in Europe is widening

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Prognostic importance of comorbidity in a hospital-based cancer registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Polypharmacy in elderly patients with cancer: clinical implications and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Ageing and physiological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

ESH-SIOG International Conference on Haematological Malignancies in the Elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the eld

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Integrating a geriatric evaluation in the clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

The abbreviated comprehensive geriatric assessment (aCGA) for use in the older cancer patient as a prescreen: scoring and interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Frailty Intervention Trial (FIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: a nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Validation of a model to predict perioperative mortality from lung cancer resection in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Postoperative complications in elderly patients after lung cancer surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

The emerging role of minimally invasive surgical techniques for the treatment of lung malignancy in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Surgery of non-small cell lung cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Radiotherapy for lung cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Age and comorbidity considerations related to radiotherapy and chemotherapy administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Postoperative radiotherapy for elderly patients with stage III lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Dose adjustment and supportive care before and during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Early palliative care for patients with metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Understanding the attitudes of the elderly towards enrolment into cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Barriers to enrollment of elderly adults in early-phase cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Geriatric Oncology Research in the Cooperative Groups: A Report of a SIOG Special Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268

Endpoints for assessing drug activity in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU268